Zilbrysq (zilucoplan), billed as the first once-daily subcutaneously-administered complement C5 inhibitor, will launch onto the US market in competition with AstraZeneca’s Soliris (eculizumab) and follow-up Ultomiris (ravulizumab) – both given as intravenous infusions – which were approved for gMG in 2017 and 2022, respectively.
UCB’s drug can be self-administered by patients, and the company reckons that could prove to be an important differentiator, reducing the need for patients to travel to and from clinics and reducing interference with their daily lives.
